2 results
Approved WMOCompleted
The AlphaCore* is currently being used in some hospitalised COPD subjects, as adjunctive treatment to regular care. This use is conform CE and is showing diminished breathlessness in some subjects. For further investigation of these results, this…
Approved WMOCompleted
The overall objective of the CAB LA + RPV LA clinical development programme is to develop a highly effective, well-tolerated, two-drug, long-acting injectable regimen which has the potential to offer improved treatment convenience, compliance and…